Redeye updates on EG7 ahead of its Q2-results (due 15 August) where we expect a seasonally softer su...
Redeye provides a preview of Thunderful Group ahead of its Q2 2023 report, due on August 21.
Tallinna Sadam will publish Q2 results on 10 August 2023.
Scanfil’s Q2 results were a bit better than we estimated.
XVIVO’s peer and future competitor TransMedics continues to open up the US Heart transplant market w...
Redeye provides an update in relation to Optomed’s Q2 2023 report.
Redeye provides an update on Physitrack ahead of its Q2’23-results (scheduled for 18 August), antici...
Good demand and high utilisation ratios were behind the record-breaking operating profit in Q2.
Redeye returns with an update following Annexin’s Q2 report.
Storbritannien visar fortsatt styrka mot en svagare nordisk marknad.
Redeye provides an initial take on Optomed’s Q2 2023 report.
Enersense’s Q2 results recovered well from the challenging comparison period, and earnings should ha...
Although DT delivered solid revenue growth in Q2, the group EBIT fell short of our low expectations.
Scanfil’s Q2 results came in somewhat higher than estimated.
Following the FDA approval in 17th February earlier this year FILSPARI is recording sales of USD 3m...
CapMan's Q2 2023 EBIT fell short of Refinitiv consensus expectations, partly explained by fair value...
Following BankNordik's Q2 2023 report, we leave 2023E-25E adjusted EPS roughly unchanged.
• EBITDA PLN 60-70m vs. ABGSCe PLN 112m • Miss driven by weaker paper volumes • Destocking likely to...
SDS har stuvat om affärsstrategin med ett större fokus på att leverera standardiserad mjukvara, snar...
Redeye comments on yesterday’s ruling in the lawsuit - in which the judge ruled that the whole paten...
